The Egyptian Journal of Haematology

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 44  |  Issue : 1  |  Page : 6--13

CYP2B6 polymorphism and lipoprotein lipase expression in chronic lymphocytic leukemia: impact on the outcome of fludarabine–cyclophosphamide regimen


Ahmed M.L Bedewy1, Waleed R El-Bendary2 
1 Hematology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt
2 Clinical Pathology Department, Military Medical Academy, Cairo, Egypt

Correspondence Address:
Ahmed M.L Bedewy
Medical Research Institute, Alexandria University, Abraj Al-Shaker, Zaky Ragab Street, Smouha, Alexandria, 21615
Egypt

Background Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and has a highly variable clinical course. Cyclophosphamide (CPA)-containing regimens are the standard of care for patients lacking the 17p deletion. CYP2B6 is a polymorphic cytochrome P450 isoform that converts CPA to its active form. Lipoprotein lipase (LPL) catalyzes the hydrolysis of triacylglycerol. Remarkably, a growing body of data emphasizes its role in the biology of different tumors. Objectives This study aimed to study CYP2B6 polymorphism and LPL expression in fludarabine cyclophosphamide (FC)-treated CLL patients lacking 17p deletion. Methods 46 treatment-naïve CLL patients negative for 17p deletion and indicated to receive chemotherapy were enrolled. CYP2B6 genotyping and lipoprotein lipase mRNA expression were assayed by Realtime PCR. FC-protocol was given then treatment-related toxicities, response, and event free survival were traced. Results CYP2B6*6 allele was associated with lower rates of treatment-related anemia and hospital admission. The response to FC was affected only by CYP2B6 polymorphism. The event-free survival of responders was significantly higher in patients having low LPL expression. Conclusion CYP2B6*6 infers lower CPA efficacy with lower treatment-induced side effects and increased risk of nonresponding to FC chemotherapy in CLL. LPL expression is a predictor of outcome in CLL, indicating poor survival.


How to cite this article:
Bedewy AM, El-Bendary WR. CYP2B6 polymorphism and lipoprotein lipase expression in chronic lymphocytic leukemia: impact on the outcome of fludarabine–cyclophosphamide regimen.Egypt J Haematol 2019;44:6-13


How to cite this URL:
Bedewy AM, El-Bendary WR. CYP2B6 polymorphism and lipoprotein lipase expression in chronic lymphocytic leukemia: impact on the outcome of fludarabine–cyclophosphamide regimen. Egypt J Haematol [serial online] 2019 [cited 2022 May 28 ];44:6-13
Available from: http://www.ehj.eg.net/article.asp?issn=1110-1067;year=2019;volume=44;issue=1;spage=6;epage=13;aulast=Bedewy;type=0